Advanced Search

 

Study ID Status Title Patient Level Data
B2C104604 Completed A randomised, double-blind, placebo-controlled, dose ascending, five-way crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of a single administration of three inhaled doses (25, 100 and 400 µg) of GW642444M Study Listed on ClinicalStudyDataRequest.com
B2C106093 Completed Multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (25, 100 and 400 mcg once daily) of GW642444 Study Listed on ClinicalStudyDataRequest.com
B2C106180 Completed A single-centre, open-label, sequential, dose-ascending study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of single intravenous, inhaled and oral doses of GW642444 in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
B2C106996 Completed A randomized, single-dose, dose-ascending, double blind, placebo-controlled, 5-way crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in asthmatic patients Study Listed on ClinicalStudyDataRequest.com
B2C108562 Completed A 2-wk study to evaluate the safety, tolerability,pharmacodynamics and pharmacokinetics of GW642444H(100 administered once daily in the morning via DISKUS™ dry-powder inhaler)compared with SEREVENT(salmeterol)(50mcg administered twice daily via DISKUS dry-powder inhaler)and placebo in subject w/COPD Study Listed on ClinicalStudyDataRequest.com
B2C108784 Completed A randomised, double-blind, placebo-controlled, parallel-group, 14 day repeat dose study to investigate the safety, tolerability, pharmacokinetics and extra-pulmonary pharmacodynamics of inhaled doses of GW642444M formulated with magnesium stearate in healthy subjects Study Listed on ClinicalStudyDataRequest.com
B2C109575 Completed A randomised, double-blind, placebo controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma Study Listed on ClinicalStudyDataRequest.com
B2C110165 Completed A randomised, single-dose, dose ascending, double-blind, placebo controlled, four-way, incomplete block crossover study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M with magnesium stearate in COPD patients. Study Listed on ClinicalStudyDataRequest.com
B2C111045 Completed Study B2C111045, A Dose-Finding Study of GW642444 versus Placebo in Patients with COPD Study Listed on ClinicalStudyDataRequest.com
B2C111401 Completed A randomised, single-dose, dose-ascending, double-blind, placebo-controlled, 5-way crossover study to investigate the efficacy, pharmacokinetics and pharmacodynamics of inhaled doses of GW642444M in asthmatic patients Study Listed on ClinicalStudyDataRequest.com
B2E106359 Completed A multi-enter, randomized, double-blind, placebo-controlled, four-way incomplete block crossover study to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (10, 15, and 20 mcg) of GSK159797 Study Listed on ClinicalStudyDataRequest.com
B2F104300 Completed A randomised, double-blind, placebo controlled study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled dry powder doses of GSK159802 in healthy male subjects and asthmatics Study Listed on ClinicalStudyDataRequest.com
B3I105940 Completed A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the beta-3-Adrenergic Receptor Agonist Solabegron in Subjects with Irritable Bowel Syndrome
B3P104833 Completed An Eight- Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile of oral Solabegron (GW427353) 125mg and 50mg Administered Twice Daily vs Placebo in Women with Overactive Bladder
BCM30002 Completed A Single-Centre, Randomised, Double-Blind, Three Way Crossover Study to Investigate Longitudinal Growth, Using Knemometry, in Children with Mild Asthma During Treatment with Beclomethasone Dipropionate 400?g bd (800?g/Day), Beclomethasone Dipropionate 200?g bd (400?g/Day) and Fluticasone Propion ...
BCR10001 Completed A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) in Combination with 2.0 mg Oral Topotecan in Cancer Patients
BDPA/88/001 (UK20) Completed The Disposition, Metabolism and Pharmacokinetics of 14C-Lamotrigine After Single Oral Administration of 240mg (15?Ci) to Six Healthy Male Subjects
BDR3780 Completed A single dose bioequivalence study comparing a new formulation of Org31540/SR90107A and the reference formulation in healthy male subjects
BDR4979 Completed A single dose bioequivalence study comparing a new formulation of fondaparinux sodium at 12.5 mg/mL and the reference formulation at 10 mg/mL, in healthy male subjects. Open, randomized, crossover and single center study Study Listed on ClinicalStudyDataRequest.com
BEX104545 Completed Expanded Access Study of Iodine I 131 Tositumomab for Relapsed/Refractory Low-Grade and Transformed Low-Grade Non-Hodgkin's Lymphoma Study Listed on ClinicalStudyDataRequest.com
BGS105049 Completed A randomised, placebo-controlled, 4-period, incomplete block, crossover study of 7 days dosing of intranasal GW784568X (100mcg, 200mcg and 400mcg od), fluticasone propionate (200mcg od) and placebo (blinded for GW784568X vs placebo) to evaluate the efficacy and safety using an environmental chamber in male subjects with allergic rhinitis Study Listed on ClinicalStudyDataRequest.com
BON103593 Completed A one year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis Study Listed on ClinicalStudyDataRequest.com
BRL 49653/392 Completed A 52 weeks open label, randomised, parallel group, multicetre study to investigate the effects of rosiglitazone or metformin on blood pressure when administered to subjects with Impaired Glucose Tolerance
BRL-025000/672 Completed An open-label, three period crossover, incomplete block study to determine the pharmacokinetics of five novel mixed component formulations of amoxicillin once-daily in healthy volunteers.
BRL-049653/231 Completed A long term, open label, randomised study in patients with type 2 diabetes, comparing the combination of rosiglitazone and either metformin or sulfonylurea with metformin plus sulfonylurea on cardiovascular endpoints and glycaemia Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.